Search

Your search keyword '"reintroducing chemotherapy"' showing total 3 results
Start Over Descriptor "reintroducing chemotherapy"
3 results on '"reintroducing chemotherapy"'

1. Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report

Author

Natacha Dencker Trabjerg, Christina Rask, Lars Henrik Jensen, and Torben Frøstrup Hansen

Subjects
carcinoembryonic antigen, colorectal cancer, immunotherapy, pseudoprogression, reintroducing chemotherapy, Medicine, Medicine (General), R5-920
Abstract

Abstract Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency.

Published
2019
Full Text
View/download PDF

2. Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report.

Author

Trabjerg, Natacha Dencker, Rask, Christina, Jensen, Lars Henrik, and Hansen, Torben Frøstrup

Subjects
*THERAPEUTICS, *COLORECTAL cancer, *METASTASIS, *CARCINOEMBRYONIC antigen, *CANCER chemotherapy
Abstract

Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

3. Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report

Author

Torben Hansen, Natacha D. Trabjerg, Christina Rask, and Lars Henrik Jensen

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, pseudoprogression, lcsh:Medicine, Case Report, colorectal cancer, Pembrolizumab, Case Reports, 030204 cardiovascular system & hematology, Treatment failure, 03 medical and health sciences, 0302 clinical medicine, Carcinoembryonic antigen, Internal medicine, medicine, reintroducing chemotherapy, Pseudoprogression, Chemotherapy, lcsh:R5-920, biology, business.industry, carcinoembryonic antigen, Disease progression, lcsh:R, General Medicine, Immunotherapy, medicine.disease, 030220 oncology & carcinogenesis, biology.protein, immunotherapy, business, lcsh:Medicine (General)
Abstract

Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results